Revelation Biosciences, Inc. (NASDAQ:REVB) Short Interest Update

Revelation Biosciences, Inc. (NASDAQ:REVB) saw a significant decrease in short interest in August. As of August 31st, there was short interest totaling 582 shares, a decrease of 96.2% from the August 15th total of 15,394 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average trading volume of 61,763 shares, the short-interest ratio is currently 0.0 days.

Hedge Funds Weigh In On Revelation Biosciences

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC acquired a new position in Revelation Biosciences in the 4th quarter valued at about $27,000. Armistice Capital LLC purchased a new position in shares of Revelation Biosciences in the 3rd quarter valued at approximately $114,000. Finally, Sabby Management LLC grew its stake in shares of Revelation Biosciences by 192.5% in the 4th quarter. Sabby Management LLC now owns 605,702 shares of the company’s stock valued at $484,000 after purchasing an additional 398,651 shares during the last quarter. Hedge funds and other institutional investors own 12.80% of the company’s stock.

Revelation Biosciences Trading Down 0.7%

Shares of Revelation Biosciences stock traded down $0.01 during trading on Friday, reaching $0.99. The company’s stock had a trading volume of 3,617 shares, compared to its average volume of 40,349. The company has a 50-day moving average price of $1.06 and a two-hundred day moving average price of $1.11. Revelation Biosciences has a fifty-two week low of $0.88 and a fifty-two week high of $8.04. The firm has a market cap of $3.95 million, a PE ratio of -0.08 and a beta of -0.14.

Revelation Biosciences (NASDAQ:REVB) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.87) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.01. On average, analysts predict that Revelation Biosciences will post -5.18 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings downgraded Revelation Biosciences from a “sell (e+)” rating to a “sell (e)” rating in a report on Tuesday, August 25th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has a consensus rating of “Sell”.

About Revelation Biosciences

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.